The $2 Trillion Valuation Debate Skips What Anthropic Knows 
Pharmacore secures funding to improve medication regimen reviews in long-term care Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company…
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company…
Parexel Appoints Scott Smith, M.D., Ph.D. as New Head of Hematology
Addition of new therapeutic expert reflects company’s commitment to drug development in hematology DURHAM, N.C.,…
Parexel Appoints Scott Smith, M.D., Ph.D. as New Head of Hematology
Addition of new therapeutic expert reflects company’s commitment to drug development in hematology DURHAM, N.C.,…
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting
Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the…
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting
Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the…
Ambrx Presents New Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM),…
Ambrx Presents New Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) — Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM),…
Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials
BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical…
Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials
BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical…
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan
— The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population…
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan
— The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population…
Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company…
Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company…
IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for…
IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for…
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™…
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™…
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month
Broadcasting Live on Wednesday April 19th at 3:45 PM ET TARRYTOWN, NY, April 19, 2023…
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month
Broadcasting Live on Wednesday April 19th at 3:45 PM ET TARRYTOWN, NY, April 19, 2023…